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Abstract
Aims: The aim of this study was to determine whether the Joint European Societies guidelines on secondary cardio-
vascular prevention are followed in everyday practice.
Design: A cross-sectional ESC-EORP survey (EUROASPIRE V) at 131 centres in 81 regions in 27 countries.
Methods: Patients (<80 years old) with verified coronary artery events or interventions were interviewed and exam-
ined 6 months later.
Results: A total of 8261 patients (females 26%) were interviewed. Nineteen per cent smoked and 55% of them were
persistent smokers, 38% were obese (body mass index 30 kg/m2), 59% were centrally obese (waist circumference: men
102 cm; women 88 cm) while 66% were physically active <30min 5 times/week. Forty-two per cent had a blood
pressure 140/90mmHg (140/85 if diabetic), 71% had low-density lipoprotein cholesterol 1.8mmol/L (70mg/dL)
and 29% reported having diabetes. Cardioprotective medication was: anti-platelets 93%, beta-blockers 81%, angiotensin-
converting enzyme inhibitors/angiotensin receptor blockers 75% and statins 80%.
Conclusion: A large majority of coronary patients have unhealthy lifestyles in terms of smoking, diet and sedentary
behaviour, which adversely impacts major cardiovascular risk factors. A majority did not achieve their blood pressure,
low-density lipoprotein cholesterol and glucose targets. Cardiovascular prevention requires modern preventive cardi-
ology programmes delivered by interdisciplinary teams of healthcare professionals addressing all aspects of lifestyle and
risk factor management, in order to reduce the risk of recurrent cardiovascular events.
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Introduction
The main objectives of cardiovascular disease (CVD)
prevention are to prevent prematuremorbidity andmor-
tality, improve quality of life and reduce increasing
healthcare costs.1–6 CVD remains a leading cause of
death across Europe with about 44% of the deaths
related to coronary heart disease (CHD).7 The
European Society of Cardiology (ESC), together with
other partners, has engaged in a comprehensive pro-
gramme of CVD prevention in clinical practice for
almost 25 years. Joint European Societies (JES)
recommendations, first published in 1994, have been
updated five times, most recently in 2016,1–6 with the
aim to promote evidence-based preventive cardiology
by encouraging national guidance on CVD prevention
and its communication, implementation and regular
audit. Implementation of these guidelines has been
repeatedly evaluated by the EUROASPIRE (European
Action on Secondary and Primary Prevention by
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Intervention toReduce Events) surveys.8–15 The fourth and
fifth EUROASPIRE surveys merged with the EuroHeart
Survey on Diabetes.13,14,16,17 From 2012 EUROASPIRE
has been part of the EURObservational Research
Programme (EORP) of the ESC.
EUROASPIRE V was performed to identify risk fac-
tors in coronary patients with and without diabetes,
describe their management through lifestyle modifications
and use of drug therapies in order to provide an objective
assessment of the implementation of current evidence-
based CVD prevention. This report focuses on lifestyle
adaptation and the control of blood pressure, low-density
lipoprotein cholesterol (LDL-C) and diabetes.
Study population and methods
Geographical area and hospital sampling frame
EUROASPIRE V is a cross-sectional study carried out
in 2016–2017 in 27 countries as listed in the
Supplementary Material Table 1 online. At least one
geographical area with a defined population was
selected within each country and their serving hospitals
(a minimum of two) identified in order to provide any
patient with acute coronary symptoms, or requiring
revascularization (percutaneous coronary intervention
(PCI) or coronary artery bypass surgery (CABG), with
a similar chance of being included.
Consecutive patients (18 to <80 years old) were
identified from diagnostic registers, hospital discharge
lists or other sources with a first or recurrent clinical
diagnosis or treatment of (i) elective or emergency
CABG, (ii) elective or emergency PCI, (iii) acute myo-
cardial infarction (ICD-10 I21) and (iv) acutemyocardial
ischaemia (ICD-10 I20). The starting date for identifica-
tion was 6 months to <2 years prior to date of study
interview. Eligible patients were invited to attend a study
visit. The invitation procedure varied between countries,
depending on local data protection rules.
Data collection and definitions
The ESC EUROASPIRE V registry conducted by
EURObservational Research Programme (EORP) is a
cross-sectional survey performed in 131 centres in 81
regions in 27 countries within the European Society
of Cardiology. Data collection was undertaken by cen-
trally trained research staff, who, within the stated time
window, reviewed patient medical records and inter-
viewed and examined the patients using standardized
methods and similar instruments at all centres.
Information on personal and demographic details,
smoking status, history of obesity, hypertension, dysli-
pidaemia, glucose metabolism and medication was
obtained from medical records. Self-reported
information on lifestyle, other risk factor management
and medication was obtained at interview. The self-
reported questionnaires were all validated versions for
each country. The following measurements were
performed:
Smoking at the time of interview was defined as self-
reported smoking and/or a breath carbon monoxide
exceeding 10 ppm18 by means of Smokerlyzer
(Bedfont Scientific, Model Microþ). Persistent smoking
was defined as smoking at time of interview among
those who smoked in the month prior to the index event.
Height and weight were measured in light indoor
clothes without shoes (SECA scales 701 and measuring
stick model 220). Overweight was defined as a body
mass index (BMI) 25 to <30 kg/m2 and obesity as
BMI 30 kg/m2.
Waist circumference was measured using a metal
tape horizontally in the mid-axillary line midway
between the lowest rim of the rib cage and tip of the
hip bone with the patient standing.19 Abdominal over-
weight was defined as a waist circumference of 80 to
<88 cm for women and 94 to <102 cm for men and
central obesity as a waist circumference of 88 cm for
women and 102 cm for men.
The physical activity target was defined by the follow-
ing question: ‘‘Do you take regular physical activity of at
least 30 minutes’ duration on average five times a week?’’
Blood pressure was measured twice on the right
upper arm in a sitting position using an automatic digi-
tal sphygmomanometer (Omron M6). The mean was
used for analysis with raised blood pressure defined as
140/90mmHg (140/85mmHg if diabetes).
Venous (fasting) blood was drawn for serum total
and high-density lipoprotein cholesterol (HDL-C), tri-
glycerides and glycated haemoglobin (HbA1c). The
LDL-C was calculated by Friedewald’s formula.20
Elevated LDL-C concentration was defined as
1.8mmol/L (70mg/dL). Plasma glucose was ana-
lysed locally with a point-of-care technique (Glucose
201RT, HemoCue, A¨ngelholm, Sweden).21 Elevated
fasting glucose among patients with diabetes was
defined as 6.0mmol/L (110mg/dL) and elevated
HbA1c as 7.0% (International Federation of
Clinical Chemistry (IFCC)  53mmol/mol).
The Laboratory in the National Institute for Health
and Welfare (Helsinki, Finland), accredited by the
Finnish Accreditation Service and fulfilling require-
ments of the standard SFS-EN ISO/IEC 17025:2005,
acted as the central laboratory. Venous blood was
taken into a tube containing clot activator (Vacutainer
SST II Advanced, Becton Dickinson) for lipid assays
and into a potassium EDTA tube (Vacutainer
K2EDTA) for HbA1c assay. Samples were stored
locally at –70C. All measurements were performed on
a clinical chemistry analyser (Architect c8000; Abbott
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Laboratories, Abbott Park, Illinois, USA). Total chol-
esterol, HDL-C, creatinine and triglycerides were ana-
lysed in serum, and HbA1c in whole blood.
Data management
Electronically collected data were submitted online to
the data management centre (EURObservational
Research Program (EORP), ESC, Sophia-Antipolis,
France).
Statistical analyses
Overall, sample size calculations indicated that groups
of 400 patients were sufficient to produce prevalence
estimates with a precision of at least 5% with 95%
confidence. Descriptive statistics were used to estimate
the prevalence of risk factors and medication use at
interview. Patients’ demographics, risk factor profiles
and use of medication were described according to
means, standard deviations and proportions. Relevant
comparisons of risk factor prevalences were evaluated
according to mixed logistic regression analyses account-
ing for clustering of patients within countries
and with additional adjustment for age and gender.
All analyses were undertaken using SAS statistical soft-
ware (release 9.4) in the Department of Public Health,
Ghent University, Belgium.
Ethical procedures. National Co-ordinators were respon-
sible for obtaining Local Ethics Committees approvals.
Written, informed consent was obtained from each par-
ticipant and stored in the patient file.
Outcome measures. The main outcome measures were
the proportions of coronary patients achieving the
lifestyle, risk factor and therapeutic targets as defined
in the 2016 guidelines on CVD prevention.6
Results
The survey was undertaken at 131 centres covering 81
geographical regions in 27 countries: Belgium, Bosnia &
Herzegovina, Bulgaria, Croatia, Czech Republic,
Egypt, Finland, Germany, Greece, Ireland, Italy,
Kazakhstan, Kyrgyzstan, Latvia, Lithuania, The
Netherlands, Poland, Portugal, Romania, Russia,
Serbia, Slovenia, Spain, Sweden, Turkey, Ukraine and
the UK. A total of 16,208 medical records were reviewed
and 8261 patients attended the interview with a partici-
pation rate (excluding patients who died, moved away
or had a change in medical condition) of 56%.
Supplementary Table 1 lists the countries, geographical
regions and numbers of patients attending interview.
The median time between the index event and the
interview was 1.1 years (interquartile range 0.8–1.6).
The reasons for not being interviewed were: no
response to the invitation letter 56%, refusal to
attend for personal reasons 38%, miscellaneous 6%.
Patient characteristics at interview are presented in
Table 1. Overall, the mean (SD) age at interview was
64 (10) years and 26% were women. Following their
index event 78% were under care of a cardiologist
and/or a general practitioner (57%), a diabetologist/
endocrinologist (11%) and/or a specialist cardiac
nurse (4%), with wide variation between countries.
Smoking, body weight and physical activity
Results on smoking, overweight and obesity and phys-
ical activity are shown in Table 2. The overall
prevalence of smoking at time of interview was 19%
Table 1. Patients’ characteristics at interview.
Characteristics
All
N¼ 8261
Men
n¼ 6132
Women
n¼ 2129
Age, mean (SD) 63.6 (9.6) 63.0 (9.7) 65.4 (9.2)
<50 years, % (n) 9.3 (772) 10.3 (630) 6.7 (142)
50–59 years, % (n) 24.7 (2043) 26.4 (1619) 19.9 (424)
60–69 years, % (n) 38.1 (3150) 38.0 (2330) 38.5 (820)
70 years, % (n) 27.8 (2296) 25.3 (1553) 34.9 (743)
Medical history
Hospitalization for CABG, % (n) 18.6 (1535) 20.4 (1253) 13.2 (282)
PCI, % (n) 80.2 (6629) 82.1 (5035) 74.9 (1594)
ACS without revascularization, % (n) 11.1 (919) 8.4 (516) 18.9 (403)
Stroke, % (n) 4.1 (341) 3.7 (229) 5.3 (112)
Peripheral artery disease, % (n) 2.7 (221) 2.7 (167) 2.5 (54)
CABG: coronary artery bypass graft surgery; PCI: percutaneous coronary intervention; ACS: acute coronary syndrome
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(Figure 1). The prevalence of persistent smoking among
those who smoked in the month prior to the coronary
event was 55% and 53% intended to quit smoking
within the next six months. Although 85% of persistent
smokers had been offered professional advice to quit,
only 23% tried to stop and only a small proportion
(5%) attended a smoking cessation clinic. Nicotine
replacement therapy, bupropion and varenicline, were
prescribed to a small minority: 7%, 1% and 2% of
these patients respectively.
Overall, 44% of patients were overweight and 38%
were obese. The prevalence of central obesity was 59%,
markedly higher in women than in men. One in four
obese patients reported never being told they were over-
weight and 23% reported not having had a weight
measurement after hospital discharge. Only half of
the obese patients had tried to lose weight while 59%
were considering losing weight in the next six months.
Thirty-eight per cent of obese and 40% of centrally
obese patients had not obtained dietary guidelines
and were not aware of their weight target.
Two-thirds (66%) of patients (men 63%; women
73%, p< 0.0001) were not achieving the defined phys-
ical activity target. Vigorous activities were taken up by
only 16%. Fifty-eight per cent of the patients intended
to become more active. Almost half of the patients
(46%) did not recall having received personal advice
on physical activity.
Blood pressure, lipids and diabetes
The management of blood pressure, LDL-C and self-
reported diabetes is presented in Table 3. Overall, 95%
of patients were on blood pressure lowering drugs (beta-
Table 2. Patients’ lifestyles at the time of interview.
Lifestyle characteristics
All
N¼ 8261
Men Women
Aged
< 60 years
n¼ 2249
Aged
 60 years
n¼ 3883
Aged
< 60 years
n¼ 566
Aged
 60 years
n¼ 1563
Smoking 19% 31% 15% 21% 10%
Persistent smoking 55% 54% 54% 59% 54%
Persistent smokers not having been offered professional advice
to quit
15% 14% 15% 12% 18%
Persistent smokers not having attempted to quit smoking since
hospital discharge
77% 76% 79% 73% 77%
Persistent smokers not having the intention to quit within the
next six months
53% 49% 58% 57% 56%
Overweight and obesity 82% 84% 81% 83% 80%
Obesity 38% 38% 33% 51% 44%
Central obesity 59% 50% 53% 80% 77%
Obese patients never been told they are overweight 24% 24% 25% 23% 24%
Obese patients not having attempted actively to lose weight in
last month
50% 47% 52% 45% 54%
Obese patients not seriously considering weight loss in next
six months
41% 33% 43% 43% 46%
Obese patients not being aware of their weight target 40% 38% 36% 54% 43%
Obese patients not having been advised to follow dietary
guidelines
38% 35% 40% 40% 36%
Regular physical activity 30min on average five times a week 34% 39% 35% 28% 27%
Vigorous physical activity for 20min at least three times a
week
16% 21% 16% 16% 10%
Performing planned physical activity to increase physical fitness 35% 39% 36% 28% 27%
Not performing planned physical activity and no intention to
do so in next six months
42% 33% 43% 42% 51%
Not having received personal advice to do more general
everyday activities
46% 41% 47% 47% 49%
Smoking: self-reported smoking or >10 ppm carbon monoxide in breath; persistent smoking: self-reported smoking or >10 ppm carbon monoxide in
breath in patients reporting to have been smoking in the month prior to the index event; overweight: body mass index (BMI) 25 to <30 kg/m2;
obesity: BMI 30 kg/m2; central obesity: waist circumference 88 cm for women and 102 cm for men.
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Table 3. Cardiovascular risk factor management at the time of interview.
Risk factor
All
N¼ 8261
Men Women
Aged
< 60 years
n¼ 2249
Aged
 60 years
n¼ 3883
Aged
< 60 years
n¼ 566
Aged
 60 years
n¼ 1563
Systolic/diastolic blood pressure 130/80mmHg 71% 68% 74% 65% 72%
Systolic/diastolic blood pressure 140/90mmHg (140/85 if
diabetes)
42% 35% 46% 38% 44%
Systolic/diastolic blood pressure 160/100mmHg 12% 9% 13% 12% 13%
Using blood pressure lowering drugs 95% 93% 96% 94% 97%
Using drugs specifically to lower blood pressure 78% 69% 80% 78% 85%
Raised blood pressure in patients using drugs specifically to lower
blood pressure
46% 40% 50% 44% 48%
Reporting 100% compliance with blood pressure lowering drugs 76% 79% 71% 74% 79%
If blood pressure raised, never been told by a doctor they have high
blood pressure
15% 20% 16% 12% 8%
LDL-C 1.8mmol/L 71% 71% 67% 79% 77%
LDL-C 2.5mmol/L 37% 37% 32% 50% 45%
If LDL-C 2.5mmol/L, never been told they have high cholesterol 29% 34% 29% 30% 18%
Using lipid-lowering drugs 84% 85% 86% 76% 82%
Using high-intensity lipid-lowering drugs 50% 53% 50% 47% 45%
Reporting 100% compliance with lipid-lowering drugs 81% 71% 74% 78% 82%
LDL-C 1.8mmol/L in patients using lipid-lowering drugs 68% 68% 65% 76% 74%
Self-reported previous diagnosis of diabetes 29% 22% 32% 29% 35%
Treatment of diabetes: diet 57% 54% 55% 60% 61%
Insulin 32% 26% 30% 46% 37%
Oral antidiabetic drugs 74% 77% 75% 65% 70%
In patients with known diabetes, HbA1c 7.0% 46% 48% 41% 65% 47%
LDL-C: low-density lipoprotein cholesterol; HbA1c: glycated haemoglobin
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Figure 1. Prevalence of smoking (%) by age and gender at the time of the interview. Self-reported smoking or > 10 ppm
CO in breath.
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blockers, angiotensin-converting enzyme (ACE) inhibi-
tors, angiotensin receptor blockers (ARBs), renin
inhibitors, calcium-channel blockers, diuretics or
other antihypertensives) and 78% of them confirmed
they were on medication specifically to lower their
blood pressure. The proportion with a blood pressure
130/80mmHg was 71% while 42% had a blood pres-
sure of 140/90 (140/85mmHg if diabetic) and 12%
160/100mmHg. Fifteen per cent of patients with a
blood pressure 140/90mmHg (140/85mmHg if dia-
betic) had never been told they had high blood pres-
sure. Of patients prescribed drugs to lower their blood
pressure 54% were at, or below, their recommended
blood pressure target and 76% reported complete
adherence with the intake of their blood pressure low-
ering drugs.
The proportion of patients with a LDL-C level
1.8mmol/L (70mg/dL) was 71%, and 37% of all
patients had a LDL-C 2.5mmol/L (100mg/dL). In
those with a LDL-C 2.5mmol/L (100mg/dL) 29%
had never been informed of raised cholesterol and 21%
had not had a cholesterol measurement since hospital
discharge. Lipid-lowering drugs were prescribed to
84%. Eighty per cent were taking statins and 50% of
those on lipid-lowering drugs were taking high-intensity
lipid-lowering drugs, or drug combinations, that may
reduce LDL-C by >50%. Among patients on lipid-low-
ering drugs 32% had the target level of LDL-
C< 1.8mmol/L (<70mg/dL), less so in women than
in men (p< 0.0001). Of patients on lipid-lowering
drugs 76% reported full prescription compliance.
Twenty-nine per cent of all patients reported they
had diabetes. Management with diet, insulin and oral
glucose lowering drugs was 57%, 32% and 74%
respectively. A HbA1c 7.0% (53mmol/mol) was rec-
orded in 46% of these patients. Sixteen per cent of
patients with known diabetes had not had a glucose
measurement after discharge.
Less than half of patients (46%) were advised to
participate in a cardiac rehabilitation programme and
69% of those advised attended at least half of the ses-
sions; 32% of all patients.
Use of cardioprotective drugs
Antiplatelet medication was prescribed in 93% of
patients, 81% were on beta-blockers and 75% on
ACE inhibitors or ARBs.
Relations between lifestyle and risk factors
LDL-C was less well controlled among smokers than
among non-smokers (p¼ 0.001). A higher proportion
of smokers (75%) had a LDL-C 1.8mmol/L
(70mg/dL) compared with non-smokers (69%,
p< 0.0001). Overweight and obesity were associated
with raised blood pressure and poorly controlled dia-
betes (Figures 2 and 3). There was a higher proportion
with raised blood pressure with increasing BMI in both
genders (p< 0.0001). Obesity was also associated with
an elevated HbA1c in patients with diabetes (p¼ 0.001).
Discussion
The EUROASPIRE V survey revealed that a majority
of coronary patients failed to achieve the lifestyle,
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40%
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41%
47% 48%
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Figure 2. Prevalence of raised blood pressure (%) in men and women by body mass index level. Raised blood pressure: blood
pressure 140/90mmHg (140/85mmHg in patients with diabetes mellitus).
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blood pressure, lipid and glycaemic targets of the 2016
JES guidelines on CVD prevention, and unhealthy life-
styles had an adverse impact on risk factor control in
spite of a high use of cardioprotective medications.
The prevalence of smoking is a major challenge espe-
cially in patients <50 years, where 56% of men and 46%
of women were persistent smokers. Smoking cessation
after a myocardial infarction is very effective for second-
ary prevention.22,23 Despite compelling evidence smoking
cessation strategies were poorly implemented. Only half
of persistent smokers had an intention to quit smoking,
which without behavioural support, including pharma-
cotherapies, is a daunting challenge for many patients
addicted to nicotine. If encouragement and motivation
are insufficient drug therapies should be considered
early, including nicotine replacement therapies whilst
in hospital, followed by bupropion or varenicline.24
Pharmacotherapies to support smoking cessation are
effective, safe and associated with significant reductions
in re-hospitalization and all-cause mortality.25,26
Weight reduction in overweight and obese people is
recommended in order to reduce blood pressure, LDL-
C and the risk of type 2 diabetes and thus the risk of
recurrent CVD.6 Obesity was associated with poorer
blood pressure control, a higher prevalence of diabetes
and poorer glycaemic control, illustrating the adverse
impact of unhealthy lifestyles on risk factor control and
the potential of lifestyle modification to further
reduce CVD risk. Only two-fifths of obese patients
reported trying to lose weight by changing their diet
and increasing physical activity. Only half of the
patients reported receiving advice to do more general
daily physical activities. One in four of patients with a
BMI 30 kg/m2 reported they had never been told they
were overweight and less than half had tried to lose
weight after their hospitalization. Yet, over half were
considering losing weight in the next six months, illus-
trating a willingness to try.
Despite the high use of blood pressure lowering
medications just over half of patients had achieved
the recommended blood pressure goal and lipid control
was unsatisfactory in a large proportion of patients,
with more than two-thirds of patients above the
target of LDL-cholesterol <1.8mmol/L (<70mg/dL).
Prescription of lipid-lowering medication is recom-
mended to all patients with documented CHD if not
contraindicated.27 In EUROASPIRE V, four-fifths of
patients were on lipid-lowering drugs, mainly statins,
but the LDL-C was still poorly controlled, underlining
the need for more intensive cholesterol management.
Possible explanations could be that the initial doses of
statins were too low or there was little or no up-titra-
tion of doses following treatment initiation, with only
half of patients on high-intensity lipid-lowering drugs
at interview.
Nearly one-third of patients had a history of dia-
betes, of whom just over half had a satisfactory gly-
caemic control.
The results of EUROASPIRE V are in accordance
with earlier surveys of secondary prevention in Europe,
the United States and other parts of the world.28–34 The
results of Reduction of Atherothrombosis for Continued
Health (REACH) Registry,28 the WHO study on
Prevention of Recurrences of Myocardial Infarction
and Stroke (WHO-PREMISE),29 STabilization of
Atherosclerotic plaque By Initiation of darapLadIb
70%
Men
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Figure 3. Prevalence of glycated haemoglobin (HbA1c) 7.0% (%) in male and female patients with known diabetes by body mass
index level.
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TherapY (STABILITY) trial,30 the Prospective Urban
Rural Epidemiology (PURE) study,31,32 the prospective
observational LongitudinAl RegIstry oF patients with
stable coronary arterY disease (CLARIFY) study33
and the Dyslipidemia International Study (DYSIS)34
demonstrated poor control of cardiovascular risk factors
in patients with CHD.
There may be several reasons for the poor lifestyle
adherence. To persuade patients to adapt to healthier
habits needs skills in behavioural science and time
enough to explain the importance. Moreover, and as
shown by Pogosova et al.,35 a substantial proportion
of patients have anxiety and depression symptoms after
coronary heart disease events, often left with unsatis-
factory treatment. Thus, the receptivity to lifestyle
advice may be less than optimal immediately after the
coronary event and advice may have to be repeated or
reinforced when the patient is in a better condition to
accept such counselling. The scientific evidence on the
importance of achieving healthier lifestyles for second-
ary prevention in people with CHD is strong.1–6 The
importance of adherence to lifestyle changes was well
documented in the Fifth Organisation to Assess
Strategies in Acute Ischemic Syndromes (OASIS)
trial. Persistent smokers who did not adhere to diet or
exercise had a 3.8-fold increased risk of repeated events
compared with never smokers who modified their diet
and activity pattern, and adherence to dietary and exer-
cise advice was associated with a relative risk mortality
reduction of 55%.36 In the Randomized Evaluation of
Secondary Prevention by Outpatient Nurse Specialists
(RESPONSE) 2 trial the effect of comprehensive
lifestyle programmes (targeting weight reduction,
improved physical activity and smoking cessation) on
top of usual care was evaluated in 824 patients after a
recent acute coronary syndrome or coronary stenting.
The primary outcome at 12 months was defined as
improvement in 1 qualifying lifestyle-related risk
factor without deterioration in the other two. The com-
bined outcome was reached more often in the intensive
(37%) than in the control group (26%).37 In the
EUROACTION trial of a nurse-led, multidisciplinary
hospital programme for coronary patients there were
significant improvements in diet (lower saturated fat,
increased fruit and vegetables and increased oily fish
consumption) and physical activity levels, with three
times as many patients achieving the physical activity
target in comparison with usual care.38
Strengths and limitations
To warrant the representativeness of EUROASPIRE V
up to three geographical areas with a population
greater than half a million people were selected within
each country according to its size, and all hospitals
serving that population identified, with a minimum of
two within each geographical area. All centres that par-
ticipated in the previous surveys were invited, and new
centres were added from other geographical areas.
The average interview rate was low at 56%, reflecting
falling participation in medical research generally, but
also that some countries, due to data protection laws,
restricted the invitation procedure by reducing the
possibility to reinforce invitations, thereby limiting par-
ticipation rate. This may introduce a potential bias but
non-participants are more likely to have unhealthy life-
styles and poorer risk factor control and therefore the
present findings are, if anything, probably underesti-
mating the true status of preventive cardiology across
Europe. A major strength of the EUROASPIRE
surveys is that data are based on interviews and stan-
dardized methods and equipment, including central
laboratory analyses, rather than data from medical
records, which are often incomplete as regards risk
factor recording. Therefore, our survey provides high
quality comparative information on preventive cardi-
ology practice in Europe.
Conclusions
The results of EUROASPIRE V reveal that among
patients with CHD many have unhealthy lifestyles in
terms of persistent smoking and weight related dietary
factors, including sedentary behaviour. These unhealthy
lifestyles adversely impact the control of major CVD risk
factors such as hypertension, raised LDL-C and the
prevalence of diabetes and its control. Despite the high
use of cardioprotective drug therapies the majority of
patients did not achieve their blood pressure, LDL-C
and glucose targets.
Cardiovascular prevention requires a modern pre-
ventive cardiology programme with appropriate adapta-
tion to medical and cultural settings in each country.
All patients with CHD, or any other form of atheroscler-
otic disease, should be guaranteed access to such a
programme delivered by interdisciplinary teams of
healthcare professionals – nurses, dieticians, physiother-
apists or physical activity specialists, psychologists and
physicians – addressing all aspects of lifestyle, blood
pressure, lipids and glucose management, and adherence
to cardioprotective medications, in order to reduce their
risk of recurrent cardiovascular events, improve quality
of life and prolong survival.
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